In a significant move to streamline its operations, Prenetics Global Limited (NASDAQ: PRE), a leading consumer health sciences company, has announced the divestment of its majority stake in ACT Genomics Holdings Company Limited to Delta Electronics, Inc. (TWSE: 2308). The transaction, valued at up to US$71.78 million, marks a strategic shift for Prenetics as it aims to focus on its core consumer health business.
Under the terms of the agreement, Prenetics will receive approximately US$46 million in cash post-closing, significantly bolstering its financial position. With an existing cash balance of US$44 million, the company’s reserves are expected to rise to around US$86 million, providing ample resources for future growth and innovation in the health sciences sector.
Delta Electronics, a global leader in power management and smart green solutions, also brings expertise in healthcare technologies, making it a fitting acquirer for ACT Genomics. This divestment allows Prenetics to refine its portfolio and allocate resources toward expanding its consumer health offerings, including its CircleDNA platform.
The deal comes alongside Prenetics’ updated revenue outlook for 2025, with the company raising its guidance as it anticipates significant growth. The company also reported a projected 50% increase in revenue for its IM8 segment in the second quarter, highlighting its strong momentum in the consumer health market.
In addition to its strategic divestment, Prenetics has made headlines with its pioneering move to adopt a Bitcoin treasury strategy, becoming the first healthcare firm to invest $20 million in Bitcoin. This innovative financial approach underscores the company’s forward-thinking vision and adaptability in a rapidly evolving market.
As Prenetics continues to transform into a pure-play consumer health company, industry analysts are optimistic about its growth trajectory. The successful completion of this transaction and the company’s enhanced financial flexibility position it well for future expansion and innovation in the health sciences landscape.
Andrew Lee
